Clinical Activity Of Idelalisib (GS-1101), a Selective Inhibitor Of PI3Kδ, In Phase 1 and 2 Trials In Chronic Lymphocytic Leukemia (CLL): Effect Of Del(17p)/TP53 Mutation, Del(11q), IGHV Mutation, and NOTCH1 Mutation
暂无分享,去创建一个
A. Zelenetz | J. Leonard | I. Flinn | T. Kipps | K. Rai | S. O'brien | Jennifer R. Brown | J. Burger | D. Benson | R. Furman | Yeonhee Kim | C. Bello | N. Wagner-Johnston | S. Spurgeon | B. Kahl | J. Sharman | N. Lamanna | J. Barrientos | M. Schreeder | S. Vos | M. Lazarov | T. Boyd | L. Holes | R. Dansey | R. Dubowy